Bristol-Myers Squibb Stock

$46.01

0.13% today

NYSE, Aug 11, 03:46 pm CET

ISIN

US1101221083

Symbol

BMY

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Bristol-Myers Squibb Stock price

$45.95

-15.87 25.67% 5Y

NYSE, Closing price Fri, Aug 08 2025

+0.59 1.30%

ISIN

US1101221083

Symbol

BMY

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$93.5b

Enterprise Value

$129.1b

Net debt

$35.6b

Cash

$13.6b

Shares outstanding

2.0b

Valuation (TTM | estimate)

P/E

18.5 | 6.9

P/S

2.0 | 2.0

EV/Sales

2.7 | 2.8

EV/FCF

8.9

P/B

5.4

Dividends

DPS

$2.42

Yield 1Y | 5Y

5.3% | 3.5%

Growth 1Y | 5Y

4.8% | 7.6%

Payout 1Y | 3Y

-54.9% | 288.3%

Increased

18 Years

Financials (TTM | estimate)

Revenue

$47.7b | $46.7b

EBITDA

$20.2b | $17.7b

EBIT

$14.4b | $16.0b

Net Income

$5.0b | $13.5b

Free Cash Flow

$14.6b

Growth (TTM | estimate)

Revenue

2.6% | -3.3%

EBITDA

-0.9% | -13.1%

EBIT

30.4% | 38.5%

Net Income

177.2% | 251.3%

Free Cash Flow

12.6%

Financial Health

Equity Ratio

17.6%

Return on Equity

-54.8%

ROCE

21.5%

ROIC

15.6%

Debt/Equity

2.8

EPS

$2.5

FCF per Share

$7.2

Short interest

1.9%

Employees

34k

Rev per Employee

$1.4m

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

Bristol-Myers Squibb Stock Analysis

Unlock Scores for Free

??

32 Analysts have issued a Bristol-Myers Squibb forecast:

10x Buy

31%

20x Hold

63%

More details on Analyst Estimates Including Price Targets

32 Analysts have issued a Bristol-Myers Squibb forecast:

Buy

31%

Hold

63%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Bristol-Myers Squibb

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	47,704 47,704	3% 3% 100%
- Direct Costs	12,442 12,442	12% 12% 26%
Gross Profit	35,262 35,262	0% 0% 74%
- Selling and Administrative Expenses	7,355 7,355	7% 7% 15%
- Research and Development Expense	9,639 9,639	4% 4% 20%
EBITDA	20,201 20,201	1% 1% 42%
- Depreciation and Amortization	5,759 5,759	38% 38% 12%
EBIT (Operating Income) EBIT	14,442 14,442	30% 30% 30%
Net Profit	5,049 5,049	177% 177% 11%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bristol-Myers Squibb Stock News

Positive

Seeking Alpha

●

3 days ago

3 SWANs On Sale

Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a lineup of blockbuster drugs and a solid pipeline of drugs, an A S&P credit rating, and offers a safe and sizable yield. Rexford Industrial Realty owns high-value, mission-critical real estate, pays a...

Positive

Seeking Alpha

●

6 days ago

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity

Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused on growth initiatives, including AI-driven drug discovery and new partnerships. Despite near-term earnings declines, due to patent expirations, AI and pipeline opportunities offer potential upside ...

Neutral

Business Wire

●

7 days ago

Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).

More Bristol-Myers Squibb News

Company Profile

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Head office	United States
CEO	Christopher Boerner
Employees	34,100
Founded	1933
Website	www.bms.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now